

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Pancreatic cancer cells tend to exhibit a _____ mutational burden.
 - a. High
 - b. Low
2. The ongoing Phase II SWOG-S1505 trial is evaluating perioperative mFOLFIRINOX versus _____ for patients with resectable adenocarcinoma of the pancreas.
 - a. Gemcitabine monotherapy
 - b. Nab paclitaxel monotherapy
 - c. Gemcitabine in combination with nab paclitaxel
3. The Phase III PREOPANC-1 study evaluating preoperative gemcitabine-based chemoradiation therapy versus immediate surgery for patients with resectable and borderline resectable pancreatic cancer demonstrated a survival benefit with preoperative chemoradiation therapy.
 - a. True
 - b. False
4. The Phase III PRODIGE 24/CCTG PA.6 trial evaluating adjuvant mFOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma demonstrated a statistically significant improvement in _____ with mFOLFIRINOX.
 - a. Disease-free survival
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
5. PEGPH20 is _____.
 - a. An anti-PD-1/PD-L1 antibody
 - b. A MEK inhibitor
 - c. A PARP inhibitor
 - d. A pegylated formulation of a recombinant form of human hyaluronidase
6. PEGPH20 in combination with _____ has demonstrated encouraging activity and a tolerable safety profile for patients with metastatic pancreatic ductal adenocarcinoma.
 - a. FOLFIRINOX
 - b. Gemcitabine/nab paclitaxel
 - c. Both a and b
 - d. Neither a nor b
7. Common side effects that patients with advanced pancreatic cancer undergoing treatment with PEGPH20 may experience include _____.
 - a. Lower-extremity edema
 - b. Joint and/or muscle ache
 - c. Muscle spasms
 - d. Thromboembolism
 - e. All of the above
8. The ongoing Phase II SWOG-S1513 trial is evaluating FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as _____ for patients with metastatic pancreatic cancer.
 - a. First-line therapy
 - b. Second-line therapy
 - c. Late-line therapy
9. BRCA mutations occur in approximately _____ of patients with pancreatic cancer.
 - a. 0%
 - b. 5% to 10%
 - c. 30% to 40%
10. Nal-IRI is FDA approved _____ for patients with metastatic pancreatic cancer who have already received a gemcitabine-based regimen.
 - a. As monotherapy
 - b. In combination with 5-FU/LV